These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39001247)

  • 1. Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease.
    Hanouneh M; Le D; Jaar BG; Tamargo C; Cervantes CE
    Diagnostics (Basel); 2024 Jun; 14(13):. PubMed ID: 39001247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.
    Provenzano M; Puchades MJ; Garofalo C; Jongs N; D'Marco L; Andreucci M; De Nicola L; Gorriz JL; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Aug; 33(8):1569-1580. PubMed ID: 35440501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
    Nakhleh A; Abdul-Ghani M; Gazit S; Gross A; Livnat I; Greenbloom M; Yarden A; Khazim K; Shehadeh N; Melzer Cohen C
    Diabetes Obes Metab; 2024 Aug; 26(8):3058-3067. PubMed ID: 38680053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
    Rossing P; Filippatos G; Agarwal R; Anker SD; Pitt B; Ruilope LM; Chan JCN; Kooy A; McCafferty K; Schernthaner G; Wanner C; Joseph A; Scheerer MF; Scott C; Bakris GL;
    Kidney Int Rep; 2022 Jan; 7(1):36-45. PubMed ID: 35005312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
    Eissing T; Goulooze SC; van den Berg P; van Noort M; Ruppert M; Snelder N; Garmann D; Lippert J; Heinig R; Brinker M; Heerspink HJL
    Diabetes Obes Metab; 2024 Mar; 26(3):924-936. PubMed ID: 38037539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.
    Vizcaya D; Kovesdy CP; Reyes A; Pessina E; Pujol P; James G; Oberprieler NG
    J Comp Eff Res; 2023 Aug; 12(8):e230076. PubMed ID: 37387399
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.
    Morita R; Tsukamoto S; Obata S; Yamada T; Uneda K; Uehara T; Rehman ME; Azushima K; Wakui H; Tamura K
    Diabetes Obes Metab; 2023 May; 25(5):1271-1279. PubMed ID: 36633511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial.
    Mårup FH; Thomsen MB; Birn H
    Clin Kidney J; 2024 Jan; 17(1):sfad249. PubMed ID: 38186886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.
    Heerspink HJL; Agarwal R; Bakris GL; Cherney DZI; Lam CSP; Neuen BL; Sarafidis PA; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen P; Perkovic V;
    Nephrol Dial Transplant; 2024 Jun; ():. PubMed ID: 38858818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
    Green JB; Mottl AK; Bakris G; Heerspink HJL; Mann JFE; McGill JB; Nangaku M; Rossing P; Scott C; Gay A; Agarwal R
    Nephrol Dial Transplant; 2023 Mar; 38(4):894-903. PubMed ID: 35700142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
    Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
    Agarwal R; Tu W; Farjat AE; Farag YMK; Toto R; Kaul S; Lawatscheck R; Rohwedder K; Ruilope LM; Rossing P; Pitt B; Filippatos G; Anker SD; Bakris GL;
    Ann Intern Med; 2023 Dec; 176(12):1606-1616. PubMed ID: 38048573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.